CD8A and neoplasm: As antigen presentation by MHC-I molecules on target cells is essential for recognition and killing by CD8+ cytotoxic T lymphocytes, it is a logical assumption that MHC-I expression by tumor cells would be needed for the efficiency of T cell-based immunotherapies such as ICIs.